Technology

Are the technologies and assumptions at the heart of healthcare AI trustworthy?

This article discusses real-time data capture and analytics in clinical trials.

Danish Gupta discuss the current strengths and weaknesses of artificial intelligence applications in life sciences.

Using intelligent automation of content creation can turn master product data into business value, writes Siniša Belina.

mHealth devices and apps that continuously monitor patient symptoms and help with adherence also are likely to reshape medical practice – and with it the products pharma produce, writes Vicki Anastasi.

Five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.

William King offers five predictions on evolution of data and predictive insights that could be critical for pharma go-to-market strategies.

Sean McCarthy, President & CEO of CytomX, outlines the company’s journey from university startup to rising star of the immuno-oncology space.

In the search for effective and efficient ways to bridge the urban/rural divide, technological advances are offering more and more solutions.

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

Pharm Exec speaks to Prognos CEO Sundeep Bhan about how the company’s unique offering will reach beyond life sciences as the long-promised benefits of AI become reality.

Selecta Biosciences CEO Dr. Werner Cautreels talks about the company's innovative technology and how his entrepreneurial experiences in big pharma prepared him for the challenge of a new startup.

Today’s model requires a fourth partner-the systems integrator

Mastering digital business strategies and tactics will enable life sciences companies to supercharge innovation and speed therapy discovery, patient centric-practices and improved health outcomes, writes Bhaskar Sambasivan.

Pharma companies today must increasingly provide evidence on real-world outcomes to differentiate and justify their products. But what is the true potential of real-world evidence studies and what are the right questions to ask in determining product performance in the marketplace?

In the second of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Extraction.

Can the pharma industry truly achieve a patient-centric supply chain? How some clinical trial logistics companies are racing ahead in making the patient a key link in the chain.

Despite delay in enforcement of Drug Supply Chain Security Act's new serialization requirement, getting compliant now is key.

In the second of three blogs on how digital strategy and a “data culture” can help define and deliver value, David Ormesher focuses on Value Creation.

Pharma companies still keep thousands of manufacturing procedures as text documents, an inefficient method can lead to defective batches, recalls and warning letters. Why not use video for training where applicable, asks Boaz Sigelman.